{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T11:00:23Z","timestamp":1793876423401,"version":"4.7.0"},"reference-count":150,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seminarsinnephrology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.semnephrol.2021.06.007","type":"journal-article","created":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T18:49:36Z","timestamp":1635274176000},"page":"358-370","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Obesity-Related Glomerulopathy: Clinical Management"],"prefix":"10.1016","volume":"41","author":[{"given":"Michal","family":"Herman-Edelstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talia","family":"Weinstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avry","family":"Chagnac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semnephrol.2021.06.007_bib0001","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/MNH.0000000000000212","article-title":"The dual roles of obesity in chronic kidney disease: a review of the current literature","volume":"25","author":"Rhee","year":"2016","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0002","doi-asserted-by":"crossref","first-page":"k5301","DOI":"10.1136\/bmj.k5301","article-title":"Adiposity and risk of decline in glomerular filtration rate: meta-analysis of individual participant data in a global consortium","volume":"364","author":"Chang","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0003","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1046\/j.1523-1755.2001.0590041498.x","article-title":"Obesity-related glomerulopathy: an emerging epidemic","volume":"59","author":"Kambham","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0004","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nrneph.2016.75","article-title":"Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis","volume":"12","author":"D'Agati","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0005","doi-asserted-by":"crossref","first-page":"F817","DOI":"10.1152\/ajprenal.2000.278.5.F817","article-title":"Glomerular hemodynamics in severe obesity","volume":"278","author":"Chagnac","year":"2000","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0006","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1681\/ASN.2017020222","article-title":"FXR\/TGR5 dual agonist prevents progression of nephropathy in diabetes and obesity","volume":"29","author":"Wang","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0007","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/MNH.0000000000000374","article-title":"Bile acid receptors and the kidney","volume":"27","author":"Herman-Edelstein","year":"2018","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0008","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S2213-8587(14)70065-8","article-title":"Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease","volume":"2","author":"de Vries","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0009","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1159\/000499486","article-title":"Consequences of glomerular hyperfiltration: the role of physical forces in the pathogenesis of chronic kidney disease in diabetes and obesity","volume":"143","author":"Chagnac","year":"2019","journal-title":"Nephron"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0010","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S0272-6386(01)80120-7","article-title":"Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephritis","volume":"37","author":"Bonnet","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0011","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1093\/ndt\/gfi201","article-title":"Synergy of low nephron number and obesity: a new focus on hyperfiltration nephropathy","volume":"20","author":"Praga","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0012","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1093\/ndt\/gfv214","article-title":"Recipient obesity and outcomes after kidney transplantation: a systematic review and meta-analysis","volume":"30","author":"Hill","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0013","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1681\/ASN.2017070819","article-title":"Overweight and obesity are predictors of progression in early autosomal dominant polycystic kidney disease","volume":"29","author":"Nowak","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0014","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.2215\/CJN.02250409","article-title":"Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis","volume":"4","author":"Navaneethan","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0015","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gft302","article-title":"Effects of weight loss on renal function in obese CKD patients: a systematic review","volume":"28","author":"Bolignano","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0016","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.jand.2015.02.031","article-title":"Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials","volume":"115","author":"Franz","year":"2015","journal-title":"J Acad Nutr Diet"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0017","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1053\/j.ajkd.2020.08.016","article-title":"Strategies to treat obesity in patients with CKD","volume":"77","author":"Chintam","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0018","doi-asserted-by":"crossref","DOI":"10.1159\/000513868","article-title":"Which patients with obesity are at risk for renal disease?","author":"Sandino","year":"2021","journal-title":"Nephron"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0019","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1681\/ASN.2020101472","article-title":"Management of obesity in adults with CKD","volume":"32","author":"Friedman","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0020","doi-asserted-by":"crossref","first-page":"E875","DOI":"10.1503\/cmaj.191707","article-title":"Obesity in adults: a clinical practice guideline","volume":"192","author":"Wharton","year":"2020","journal-title":"CMAJ"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0021","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2020.11.003","article-title":"KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease","volume":"99","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0022","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","article-title":"Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0023","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1681\/ASN.2010090969","article-title":"ACE inhibition is renoprotective among obese patients with proteinuria","volume":"22","author":"Mallamaci","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0024","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0025","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.semnephrol.2012.12.002","article-title":"The role of the renin-angiotensin-aldosterone system in obesity-related renal diseases","volume":"33","author":"Ruster","year":"2013","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0026","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2020.06.019","article-title":"KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease","volume":"98","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0027","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.120.048740","article-title":"Blood pressure effects of canagliflozin and clinical outcomes in type 2 diabetes and chronic kidney disease: insights from the CREDENCE trial","volume":"143","author":"Ye","year":"2021","journal-title":"Circulation."},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0028","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/jdi.12971","article-title":"Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: results from the EMPA-REG OUTCOME\u00ae trial","volume":"10","author":"Kadowaki","year":"2019","journal-title":"J Diabetes Investig"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0029","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0030","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1159\/000506533","volume":"51","author":"Weir","year":"2020","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0031","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0032","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0033","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0034","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0035","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"7","author":"Neuen","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0036","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0037","doi-asserted-by":"crossref","first-page":"F412","DOI":"10.1152\/ajprenal.00445.2017","article-title":"Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study","volume":"314","author":"Rajasekeran","year":"2018","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0038","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1161\/CIRCULATIONAHA.120.051675","article-title":"Effect of dapagliflozin on clinical outcomes in patients with chronic kidney disease, with and without cardiovascular disease","volume":"143","author":"McMurray","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0039","first-page":"1093","article-title":"cardiovascular outcomes, and mortality in type 2 diabetes","volume":"374","author":"Rosenstein","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0040","article-title":"Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice","author":"Oshima","year":"202199999","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0041","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1093\/ckj\/sfaa198","article-title":"SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia","volume":"13","author":"Fernandez-Fernandez","year":"2020","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0042","first-page":"389","article-title":"Dapagliflozin in patients with chronic kidney disease. Reply","volume":"384","author":"Heerspink","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0043","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1053\/j.ajkd.2020.05.014","article-title":"We can finally stop worrying about SGLT2 inhibitors and acute kidney injury","volume":"76","author":"Sridhar","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0044","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002983","article-title":"Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: a systematic review and meta-analysis","volume":"16","author":"Menne","year":"2019","journal-title":"PLoS Med"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0045","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1194\/jlr.P040501","article-title":"Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy","volume":"55","author":"Herman-Edelstein","year":"2014","journal-title":"J Lipid Res"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0046","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3390\/ijms19010137","article-title":"The sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents renal and liver disease in Western diet induced obesity mice","volume":"19","author":"Wang","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0047","doi-asserted-by":"crossref","first-page":"5335","DOI":"10.1074\/jbc.M117.779520","article-title":"SGLT2 protein expression is increased in human diabetic nephropathy: sglt2 protein inhibition decreases renal lipid accumulation, inflammation, and the development of nephropathy in diabetic mice","volume":"292","author":"Wang","year":"2017","journal-title":"J Biol Chem"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0048","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.3390\/ijms19113481","article-title":"AMP-activated protein kinase (AMPK)-dependent regulation of renal transport","volume":"19","author":"Glosse","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0049","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.3390\/ijms21114054","article-title":"Sodium glucose co-transporter 2 inhibitor ameliorates autophagic flux impairment on renal proximal tubular cells in obesity mice","volume":"21","author":"Fukushima","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107954","article-title":"Proximal tubule mTORC1 is a central player in the pathophysiology of diabetic nephropathy and its correction by SGLT2 inhibitors","volume":"32","author":"Kogot-Levin","year":"2020","journal-title":"Cell Rep"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0051","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1007\/s12020-014-0519-0","article-title":"One-year treatment with liraglutide improved renal function in patients with type 2 diabetes: a pilot prospective study","volume":"50","author":"Zavattaro","year":"2015","journal-title":"Endocrine"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0052","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.2215\/CJN.02690320","article-title":"Decision algorithm for prescribing SGLT2 inhibitors and GLP-1 receptor agonists for diabetic kidney disease","volume":"15","author":"Li","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0053","doi-asserted-by":"crossref","first-page":"5831","DOI":"10.3390\/ijms20235831","article-title":"Bilic Curcic I. Renal benefits of SGLT 2 inhibitors and GLP-1 receptor agonists: evidence supporting a paradigm shift in the medical management of type 2 diabetes","volume":"20","author":"Nincevic","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0054","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S2213-8587(18)30268-7","article-title":"Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial","volume":"6","author":"Muskiet","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0055","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1161\/CIRCULATIONAHA.118.036418","article-title":"Effects of liraglutide versus placebo on cardiovascular events in patients with type 2 diabetes mellitus and chronic kidney disease","volume":"138","author":"Mann","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0056","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N Engl J Med."},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0057","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0058","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0059","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0060","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0061","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0062","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/dom.12808","article-title":"The effect of liraglutide on renal function: a randomized clinical trial","volume":"19","author":"von Scholten","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0063","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jdiacomp.2016.09.016","article-title":"Pleiotropic effects of liraglutide treatment on renal risk factors in type 2 diabetes: Individual effects of treatment","volume":"31","author":"Zobel","year":"2017","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0064","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1111\/dom.14067","article-title":"Exenatide once weeklydecreases urinary albumin excretion in patients with type 2 diabetes and elevated albuminuria: Pooled analysis of randomized active controlled clinical trials","volume":"22","author":"van der Aart-van der Beek","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0065","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/S0140-6736(21)00377-9","article-title":"Semaglutide and effective weight control","volume":"397","author":"Latini","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0066","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0067","doi-asserted-by":"crossref","first-page":"967","DOI":"10.3389\/fphar.2020.00967","article-title":"GLP-1 receptor agonists in diabetic kidney disease: from clinical outcomes to mechanisms","volume":"11","author":"Kawanami","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0068","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10157-020-02007-2","article-title":"Renoprotective effect of GLP-1 receptor agonist, liraglutide, in early-phase diabetic kidney disease in spontaneously diabetic Torii fatty rats","volume":"25","author":"Yamada","year":"2021","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0069","doi-asserted-by":"crossref","first-page":"F443","DOI":"10.1152\/ajprenal.00280.2019","article-title":"Glucagon-like peptide-1 receptors in the kidney: impact on renal autoregulation","volume":"318","author":"Hviid","year":"2020","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0070","article-title":"GLP-1 receptor agonist ameliorates obesity-induced chronic kidney injury via restoring renal metabolism homeostasis","volume":"13","author":"Wang","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0071","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12933-020-01029-0","article-title":"GLP-1 mediated diuresis and natriuresis are blunted in heart failure and restored by selective afferent renal denervation","volume":"19","author":"Katsurada","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0072","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa643","article-title":"The renal extraction and the natriuretic action of GLP-1 in humans depend on interaction with the GLP-1 receptor","volume":"106","author":"Asmar","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0073","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1111\/dom.12985","article-title":"Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: an 8-week, randomised, open-label trial","volume":"19","author":"Tonneijck","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0074","doi-asserted-by":"crossref","DOI":"10.1152\/ajprenal.00579.2019","article-title":"GLP-1-induced renal vasodilation in rodents depends exclusively on the known GLP-1 receptor and is lost in prehypertensive rats","volume":"318","author":"Jensen","year":"2020","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0075","doi-asserted-by":"crossref","first-page":"F963","DOI":"10.1152\/ajprenal.00259.2012","article-title":"Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice","volume":"303","author":"Rieg","year":"2012","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0076","doi-asserted-by":"crossref","first-page":"F181","DOI":"10.1152\/ajprenal.00302.2017","article-title":"Glucagon-like peptide-1 analog prevents obesity-related glomerulopathy by inhibiting excessive autophagy in podocytes","volume":"314","author":"Guo","year":"2018","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0077","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2016-218623","article-title":"Orlistat-induced oxalate nephropathy: an under-recognised cause of chronic kidney disease","volume":"2017","author":"Solomon","year":"2017","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0078","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1097\/HJH.0000000000000145","article-title":"Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity","volume":"32","author":"Jordan","year":"2014","journal-title":"J Hypertens"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0079","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s13679-018-0300-4","article-title":"Future pharmacotherapy for obesity: new anti-obesity drugs on the horizon","volume":"7","author":"Srivastava","year":"2018","journal-title":"Curr Obes Rep"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0080","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMra1514009","article-title":"Mechanisms, pathophysiology, and management of obesity","volume":"376","author":"Heymsfield","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0081","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/s41581-020-0323-4","article-title":"Bariatric surgery for the treatment of chronic kidney disease in obesity and type 2 diabetes mellitus","volume":"16","author":"Docherty","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0082","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1161\/01.CIR.0000031732.78052.81","article-title":"Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population","volume":"106","author":"Hillege","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0083","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","article-title":"Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency","volume":"75","author":"Levey","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0084","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/ajcn\/37.3.478","article-title":"Measurement of muscle mass in humans: validity of the 24-hour urinary creatinine method","volume":"37","author":"Heymsfield","year":"1983","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0085","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/ki.2014.112","article-title":"The body composition and excretory burden of lean, obese, and severely obese individuals has implications for the assessment of chronic kidney disease","volume":"86","author":"Fotheringham","year":"2014","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0086","doi-asserted-by":"crossref","first-page":"3833","DOI":"10.1007\/s11695-019-04057-2","article-title":"Prospective longitudinal trends in body composition and clinical outcomes 3 years following sleeve gastrectomy","volume":"29","author":"Sherf-Dagan","year":"2019","journal-title":"Obes Surg"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0087","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1681\/ASN.2018020176","article-title":"Bariatric surgery and kidney health","volume":"29","author":"Lieske","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0088","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.xkme.2020.08.008","article-title":"Performance of glomerular filtration rate estimating equations before and after bariatric surgery","volume":"2","author":"Chang","year":"2020","journal-title":"Kidney Med"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0089","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0090","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1093\/ndt\/gfh983","article-title":"Indexing glomerular filtration rate for body surface area in obese patients is misleading: concept and example","volume":"20","author":"Delanaye","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0091","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1053\/j.ajkd.2010.03.017","article-title":"Marked association between obesity and glomerular hyperfiltration: a cross-sectional study in an African population","volume":"56","author":"Wuerzner","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0092","doi-asserted-by":"crossref","first-page":"c224","DOI":"10.1159\/000317203","article-title":"Measuring the glomerular filtration rate in obese individuals without overt kidney disease","volume":"116","author":"Friedman","year":"2010","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0093","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1053\/j.ajkd.2010.06.005","article-title":"Obesity, glomerular hyperfiltration, and the surface area correction","volume":"56","author":"Levey","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0094","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s00394-015-0923-0","article-title":"Association between obesity and glomerular hyperfiltration: the confounding effect of smoking and sodium and protein intakes","volume":"55","author":"Ogna","year":"2016","journal-title":"Eur J Nutr"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0095","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1159\/000447365","article-title":"Cystatin C-creatinine based glomerular filtration rate equation in obese chronic kidney disease patients: impact of deindexation and gender","volume":"44","author":"Lemoine","year":"2016","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0096","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0242447","article-title":"The failure of glomerular filtration rate estimating equations among obese population","volume":"15","author":"Kittiskulnam","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0097","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1053\/j.ajkd.2014.06.016","article-title":"Gastric bypass surgery and measured and estimated GFR in women","volume":"64","author":"Lieske","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0098","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12882-017-0474-0","article-title":"Effect of large weight reductions on measured and estimated kidney function","volume":"18","author":"Scholten","year":"2017","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0099","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1053\/j.ajkd.2014.09.018","article-title":"Bariatric surgery, kidney function, insulin resistance, and adipokines in patients with decreased GFR: a cohort study","volume":"65","author":"Navaneethan","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0100","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1186\/s12882-018-1188-7","article-title":"Measurement of glomerular filtration rate in patients undergoing obesity surgery","volume":"19","author":"Chuah","year":"2018","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0101","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000357231","article-title":"Predicting the glomerular filtration rate in bariatric surgery patients","volume":"39","author":"Friedman","year":"2014","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0102","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/j.1365-2125.2008.03112.x","article-title":"Lean body mass normalizes the effect of obesity on renal function","volume":"65","author":"Janmahasatian","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0103","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1056\/NEJMoa1614329","article-title":"Single-nephron glomerular filtration rate in healthy adults","volume":"376","author":"Denic","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0104","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1038\/s41366-019-0476-z","article-title":"The estimation of GFR and the adjustment for BSA in overweight and obesity: a dreadful combination of two errors","volume":"44","author":"L\u00f3pez-Mart\u00ednez","year":"2020","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0105","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.soard.2009.01.006","article-title":"Bariatric surgery and progression of chronic kidney disease","volume":"5","author":"Navaneethan","year":"2009","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0106","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/ndt\/gfp640","article-title":"Weight loss and proteinuria: systematic review of clinical trials and comparative cohorts","volume":"25","author":"Afshinnia","year":"2010","journal-title":"Nephrol Dial Transplant"},{"issue":"Suppl 4","key":"10.1016\/j.semnephrol.2021.06.007_bib0107","doi-asserted-by":"crossref","first-page":"iv82","DOI":"10.1093\/ndt\/gft302","article-title":"Effects of weight loss on renal function in obese CKD patients: a systematic review","volume":"28","author":"Bolignano","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0108","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1016\/j.soard.2016.05.003","article-title":"Impact of bariatric surgery on renal functions in patients with type 2 diabetes: systematic review of randomized trials and observational studies","volume":"12","author":"Zhou","year":"2016","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0109","article-title":"Effects of bariatric surgery on renal function in obese patients: a systematic review and meta analysis","author":"Li","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0110","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.soard.2015.11.019","article-title":"Bariatric surgery reduces urinary albumin excretion in diabetic nephropathy: a systematic review and meta-analysis","volume":"12","author":"Upala","year":"2016","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0111","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1007\/s11695-018-3416-4","article-title":"The effects of bariatric surgery on renal outcomes: a systematic review and meta-analysis","volume":"28","author":"Bilha","year":"2018","journal-title":"Obes Surg"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0112","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.soard.2019.03.013","article-title":"Metabolic surgery improves renal injury independent of weight loss: a meta-analysis","volume":"15","author":"Scheurlen","year":"2019","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0113","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1007\/s00125-015-3595-7","article-title":"Type 2 diabetes mellitus and microvascular complications 1 year after Roux-en-Y gastric bypass: a case-control study","volume":"58","author":"Miras","year":"2015","journal-title":"Diabetologia"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0114","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/s41366-020-00707-z","article-title":"Remission and progression of pre-existing micro- and macroalbuminuria over 15 years after bariatric surgery in Swedish Obese Subjects study","volume":"45","author":"Shulman","year":"2021","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0115","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1056\/NEJMoa1600869","article-title":"Bariatric surgery versus intensive medical therapy for diabetes - 5-year outcomes","volume":"376","author":"Schauer","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0116","doi-asserted-by":"crossref","first-page":"670","DOI":"10.2337\/dc17-0487","article-title":"Clinical and patient-centered outcomes in obese patients with type 2 diabetes 3 years after randomization to Roux-en-Y Gastric bypass surgery versus intensive lifestyle management: the SLIMM-T2D study","volume":"41","author":"Simonson","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0117","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2020.0420","article-title":"Effect of gastric bypass vs best medical treatment on early-stage chronic kidney disease in patients with type 2 diabetes and obesity: a randomized clinical trial","volume":"155","author":"Cohen","year":"2020","journal-title":"JAMA Surg"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0118","doi-asserted-by":"crossref","first-page":"695","DOI":"10.3109\/00365518009095584","article-title":"Renal function and body composition before and after intestinal bypass operation in obese patients","volume":"40","author":"Br\u00f8chner-Mortensen","year":"1980","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0119","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1097\/01.ASN.0000068462.38661.89","article-title":"The effects of weight loss on renal function in patients with severe obesity","volume":"14","author":"Chagnac","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0120","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s12882-017-0474-0","article-title":"Effect of large weight reductions on measured and estimated kidney function","volume":"18","author":"von Scholten","year":"2017","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0121","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1007\/s11695-012-0851-5","article-title":"The effect of biliopancreatic diversion surgery on renal function\u2013a retrospective study","volume":"23","author":"Jose","year":"2013","journal-title":"Obes Surg"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0122","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.soard.2012.03.009","article-title":"Effect of bariatric surgery-induced weight loss on renal and systemic inflammation and blood pressure: a 12-month prospective study","volume":"9","author":"Fenske","year":"2013","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0123","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1007\/s11695-014-1486-5","article-title":"Laparoscopic sleeve gastrectomy prevents the deterioration of renal function in morbidly obese patients over 40 years","volume":"25","author":"Ruiz-Tovar","year":"2015","journal-title":"Obes Surg"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0124","first-page":"827","article-title":"Renal function in type 2 diabetes following gastric bypass","volume":"113","author":"Billeter","year":"2016","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0125","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1053\/j.ajkd.2016.09.020","article-title":"Estimated GFR before and after bariatric surgery in CKD","volume":"69","author":"Imam","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0126","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1186\/s12882-018-1188-7","article-title":"Measurement of glomerular filtration rate in patients undergoing obesity surgery","volume":"19","author":"Chuah","year":"2018","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0127","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s11695-020-04859-9","article-title":"The effects of bariatric surgery on renal, neurological, and ophthalmic complications in patients with type 2 diabetes: the Taiwan Diabesity Study","volume":"31","author":"Chang","year":"2021","journal-title":"Obes Surg"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0128","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s11255-012-0131-2","article-title":"GFR estimation in the morbidly obese pre- and postbariatric surgery: one size does not fit all","volume":"45","author":"Abouchacra","year":"2013","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0129","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.soard.2015.10.068","article-title":"Does bariatric surgery really prevent deterioration of renal function?","volume":"12","author":"Kim","year":"2016","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0130","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.soard.2015.07.003","article-title":"Effect of weight loss after bariatric surgery on kidney function in a multiethnic Asian population","volume":"12","author":"Ngoh","year":"2016","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0131","doi-asserted-by":"crossref","first-page":"561","DOI":"10.2337\/dc10-1761","article-title":"Effects of bilio-pancreatic diversion on diabetic complications: a 10-year follow-up","volume":"34","author":"Iaconelli","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0132","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1681\/ASN.2017060707","article-title":"Effect of bariatric surgery on CKD risk","volume":"29","author":"Friedman","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0133","doi-asserted-by":"crossref","first-page":"300","DOI":"10.7326\/M17-2383","article-title":"Microvascular outcomes in patients with diabetes after bariatric surgery versus usual care: a matched cohort study","volume":"169","author":"O'Brien","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0134","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/s41366-020-00707-z","article-title":"Remission and progression of pre-existing micro- and macroalbuminuria over 15 years after bariatric surgery in Swedish Obese Subjects study","volume":"45","author":"Shulman","year":"2021","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0135","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S2213-8587(17)30061-X","article-title":"Long-term incidence of microvascular disease after bariatric surgery or usual care in patients with obesity, stratified by baseline glycaemic status: a post-hoc analysis of participants from the Swedish Obese Subjects study","volume":"5","author":"Carlsson","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0136","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.2337\/dc19-1703","article-title":"Renal and cardiovascular outcomes after weight loss from gastric bypass surgery in type 2 diabetes: cardiorenal risk reductions exceed atherosclerotic benefits","volume":"43","author":"Liakopoulos","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0137","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.kint.2016.02.039","article-title":"Bariatric surgery is associated with improvement in kidney outcomes","volume":"90","author":"Chang","year":"2016","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0138","article-title":"Bariatric surgery and risk of death in persons with chronic kidney disease","author":"Coleman","year":"2021","journal-title":"Ann Surg"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0139","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/MNH.0000000000000212","article-title":"The dual roles of obesity in chronic kidney disease: a review of the current literature","volume":"25","author":"Rhee","year":"2016","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0140","series-title":"Nutrition in kidney disease","first-page":"197","article-title":"Implications and management of obesity in kidney disease","author":"Friedman","year":"2020"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0141","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1093\/ndt\/gfv214","article-title":"Recipient obesity and outcomes after kidney transplantation: a systematic review and meta-analysis","volume":"30","author":"Hill","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0142","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1001\/jamasurg.2020.0829","article-title":"Bariatric surgery and long-term survival in patients with obesity and end-stage kidney disease","volume":"155","author":"Sheetz","year":"2020","journal-title":"JAMA Surg"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0143","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.2215\/CJN.01480219","article-title":"Trends in bariatric surgery procedures among patients with ESKD in the United States","volume":"14","author":"Sheetz","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0144","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ekir.2017.01.010","article-title":"Bariatric surgery and kidney-related outcomes","volume":"2","author":"Chang","year":"2017","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0145","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1007\/s11695-018-3398-2","article-title":"Impact of early postbariatric surgery acute kidney injury on long-term renal function","volume":"28","author":"Nor Hanipah","year":"2018","journal-title":"Obes Surg"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0146","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s11695-012-0766-1","article-title":"Acute kidney injury following bariatric surgery","volume":"23","author":"Weingarten","year":"2013","journal-title":"Obes Surg"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0147","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s11695-015-1938-6","article-title":"Predictors of perioperative acute kidney injury in obese patients undergoing laparoscopic bariatric surgery: a single-centre retrospective cohort study","volume":"26","author":"Abdullah","year":"2016","journal-title":"Obes Surg"},{"key":"10.1016\/j.semnephrol.2021.06.007_bib0148","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/ki.2014.352","article-title":"Kidney stones are common after bariatric surgery","volume":"87","author":"Lieske","year":"2015","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.semnephrol.2021.06.007_bib0149","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.kint.2020.02.010","article-title":"Nomenclature for kidney function and disease: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference","volume":"97","author":"Levey","year":"2020","journal-title":"Kidney Int"},{"issue":"10","key":"10.1016\/j.semnephrol.2021.06.007_bib0150","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1007\/s11695-015-1819-z","article-title":"Improvement of Kidney Function Following Bariatric Surgery: Hope or Illusion?","volume":"25","author":"Favre","year":"2015","journal-title":"Obes Surg"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929521000917?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929521000917?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T23:38:26Z","timestamp":1759448306000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929521000917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":150,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S0270929521000917"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2021.06.007","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Obesity-Related Glomerulopathy: Clinical Management","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nephrology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semnephrol.2021.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}